PTO/SB/21 (08-03)

Approved for use through 08/30/2003, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE are required to respond to a collection of information unless it displays a valid OMB control number. aperwork Reduction Act of 1995, no persons **Application Number** 10/705,996 TRANSMITTAL Filing Date 11/13/2003 **FORM** First Named Inventor Platteeuw Art Unit 1615 (to be used for all correspondence after initial filing) **Examiner Name** Unassigned Attorney Docket Number

AUG 2 5 2004

Total Nur	mber of Pages in This Submission	14	Altorney booker value	SYN-0053	3		
ENCLOSURES (Check all that apply)							
Am Ext Exp ✓ Info Cer Doo Res	Fee Attached Fee Attached After Final Affidavits/declaration(s) After Sinal Affidavits/declaration(s) After Final Affidavits/declaration(s) Affidavits/declaration(s)	Rema		Copa	After Allowance communication to Technology Center (TC) Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): ppies of non-US patent documents (10 ages)		
	SIGNA	TURE C	OF APPLICANT, ATTORN	EY, OR A	GENT		
Firm or Mark R. Buscher Reg. No. 35,006							
Signature Malarch							
Date	812512 at						
CERTIFICATE OF TRANSMISSION/MAILING							

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. Typed or printed name Mark R. Buscher Date Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Johannes J. PLATTEEUW. : Examiner: Unassigned

Serial No. 10/705,996 : Group Art Unit: 1615

Filed: Nov. 13, 2003 : Docket No.: SYN-0053

For: Pharmaceutical Pellets Comprising Tamsulosin

INFORMATION DISCLOSURE STATEMENT (Supplemental)

Commissioner of Patents and Trademarks P.O. Box 1450 Alexandria, VA 22313-1450 August 25, 2004

Sir:

Further to the Information Disclosure Statement filed August 18, 2004, applicant hereby submits a copy of the document listed on the attached PTO-1449 Form, for entry into the above-identified application and consideration by the Examiner.

This Information Disclosure Statement is being submitted before a first Office Action on the merits under 37 C.F.R. § 1.97(b), and thus no fee is due.

This Statement should not be construed as a representation that a search has been made, that information cited in the statement is considered to be and/or is material to patentability, or that information more material to examination of the present patent application does not exist.

The Examiner is specifically requested not to rely solely on the document submitted herewith.

Having complied with rules 97 and 98, applicant requests that the listed document be officially considered by the Examiner, that the Examiner initial and return a copy of the 1449

Serial No. 10/705,996

Form, and that the listed document be printed among the "References Cited" on any patent to issue from this application.

Should the Examiner have any questions regarding this application, the Examiner is requested to contact applicants' representative, Mark R. Buscher (Reg. No. 35,006) at telephone number 703 753 5256.

Respectfully submitted,

Mark R. Buscher

Registration No. 35,006

P.O. Box 161 Catharpin, VA 20143 703 753 5256

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

				Complete if Known		
Substitute or form 1449/PTO				Application Number	10/705,996	
INFORMATION DISCLOSURE				Filing Date	11/13/2003	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Platteeuw	
(Use as many sheets as necessary)				Art Unit		
				Examiner Name		
Sheet	1	of	1	Attorney Docket Number	SYN-0053	

NON PATENT LITERATURE DOCUMENTS						
iner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title						
	RABASSEDA and FITZPATRICK, "Tamsulsoin: The First Prostrate-Selective alpha 1a-Adrenoceptor Antagonist for Treatment of Symptomatic Benign Prostatic Hyperplasia," Drugs of Today, vol. 32, No. 3, 1996, pp 259-268					
	Cite No.1	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. RABASSEDA and FITZPATRICK, "Tamsulsoin: The First Prostrate-Selective alpha 1a-Adrenoceptor Antagonist for Treatment of Symptomatic Benign Prostatic Hyperplasia," Drugs of Today, vol. 32, No. 3,				

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions deducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.